Biomarker in Tumor Tissue Samples From Patients With Rhabdomyosarcoma
|ClinicalTrials.gov Identifier: NCT01365962|
Recruitment Status : Completed
First Posted : June 3, 2011
Last Update Posted : May 19, 2016
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research trial studies biomarkers in tumor tissue samples from patients with rhabdomyosarcoma.
|Condition or disease||Intervention/treatment|
|Sarcoma||Genetic: gene expression analysis Other: immunohistochemistry staining method Other: laboratory biomarker analysis Other: mass spectrometry|
- To determine and quantify the degree of surface insulin-like growth factor I receptor (IGF-IR) expression in rhabdomyosarcoma (RMS) tumor tissue.
- To assess the feasibility and validity of a mass spectrometry assay for IGF-IR expression on paraffin-embedded tumor tissue.
OUTLINE: Paraffin-embedded tumor tissue slides are analyzed for insulin-like growth factor I receptor (IGF-1R) expression by mass spectrometry and correlated with the results obtained by IHC assay.
|Study Type :||Observational|
|Estimated Enrollment :||60 participants|
|Official Title:||A Study to Assess and Quantify Surface Insulin-like Growth Factor I Receptor (IGF-IR) in Rhabdomyosarcoma (RMS) Tumor Tissue|
|Study Start Date :||June 2011|
|Actual Primary Completion Date :||May 2016|
- Degree of surface IGF-IR expression in RMS tumor tissue
- Feasibility and validity of a mass spectrometry assay for IGF-IR expression on paraffin-embedded tumor tissue
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01365962
|Principal Investigator:||Suman Malempati, MD||Doernbecher Children's Hospital at Oregon Health and Science University|